Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells - PubMed (original) (raw)

. 2006 Jul 7;281(27):18601-9.

doi: 10.1074/jbc.M601887200. Epub 2006 Apr 25.

Affiliations

• PMID: 16638750
• DOI: 10.1074/jbc.M601887200

Free article

Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells

Daotai Nie et al. J Biol Chem. 2006.

Free article

Abstract

12-Lipoxygenase utilizes arachidonic acid to synthesize 12(S)-hydroperoxyeicosatetraenoic acid, which is converted to the end product 12(S)-hydroxyeicosatetraenoic acid, an eicosanoid that promotes tumorigenesis and metastasis. Increased expression of 12-lipoxygenase has been documented in a number of carcinomas. When overexpressed in human prostate or breast cancer, 12-lipoxygenase promotes tumor angiogenesis and growth in vivo. The present study was undertaken to delineate the mechanisms by which 12-lipoxygenase enhances angiogenesis. Herein we report that nordihydroguaiaretic acid, a pan inhibitor of lipoxygenases and baicalein, a selective inhibitor of 12-lipoxygenase, reduced VEGF expression in human prostate cancer PC-3 cells. Overexpression of 12-lipoxygenase in PC-3 cells resulted in a 3-fold increase in VEGF protein level when compared with vector control cells. An increase in PI 3-kinase activity was found in 12-LOX-transfected PC-3 cells and inhibition of PI 3-kinase by LY294002 significantly reduced VEGF expression. Northern blot and real time PCR analyses revealed an elevated VEGF transcript level in PC-3 cells transfected with a 12-lipoxygenase expression construct. Using a VEGF promoter luciferase construct (-1176/+54), we found a 10-fold increase in VEGF promoter activity in 12-lipoxygenase-transfected PC-3 cells. The region located between -88 and -66 of the VEGF promoter was identified as 12-lipoxygenase responsive using VEGF promoter-based luciferase assays. Further analysis with mutant constructs indicated Sp1 as a transcription factor required for 12-lipoxygenase stimulation of VEGF. Neutralization of VEGF by a function-blocking antibody significantly decreased the ability of 12-lipoxygenase-transfected PC-3 cells to stimulate endothelial cell migration, suggesting VEGF as an important effector for 12-lipoxygenase-mediated stimulation of tumor angiogenesis.

PubMed Disclaimer

Similar articles

• Elevated AKR1C3 expression promotes prostate cancer cell survival and prostate cell-mediated endothelial cell tube formation: implications for prostate cancer progression.
  Dozmorov MG, Azzarello JT, Wren JD, Fung KM, Yang Q, Davis JS, Hurst RE, Culkin DJ, Penning TM, Lin HK. Dozmorov MG, et al. BMC Cancer. 2010 Dec 6;10:672. doi: 10.1186/1471-2407-10-672. BMC Cancer. 2010. PMID: 21134280 Free PMC article.
• Platelet-type 12-lipoxygenase induces MMP9 expression and cellular invasion via activation of PI3K/Akt/NF-κB.
  Dilly AK, Ekambaram P, Guo Y, Cai Y, Tucker SC, Fridman R, Kandouz M, Honn KV. Dilly AK, et al. Int J Cancer. 2013 Oct 15;133(8):1784-91. doi: 10.1002/ijc.28165. Epub 2013 Jul 13. Int J Cancer. 2013. PMID: 23526143 Free PMC article.
• Eicosanoid regulation of angiogenesis in human prostate carcinoma and its therapeutic implications.
  Nie D, Tang K, Szekeres K, Li L, Honn KV. Nie D, et al. Ann N Y Acad Sci. 2000 Apr;905:165-76. doi: 10.1111/j.1749-6632.2000.tb06548.x. Ann N Y Acad Sci. 2000. PMID: 10818452 Review.
• Platelet-type 12-lipoxygenase activates NF-kappaB in prostate cancer cells.
  Kandouz M, Nie D, Pidgeon GP, Krishnamoorthy S, Maddipati KR, Honn KV. Kandouz M, et al. Prostaglandins Other Lipid Mediat. 2003 Jul;71(3-4):189-204. doi: 10.1016/s1098-8823(03)00042-x. Prostaglandins Other Lipid Mediat. 2003. PMID: 14518561
• Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications.
  Gao X, Porter AT, Honn KV. Gao X, et al. Adv Exp Med Biol. 1997;407:41-53. doi: 10.1007/978-1-4899-1813-0_7. Adv Exp Med Biol. 1997. PMID: 9321930 Review.

Cited by

• Mechanism of baicalein in treatment of castration-resistant prostate cancer based on network pharmacology and cell experiments.
  Dou B, Cui Y, Zhou Q, Fu J, Zhou Y, Zhang X, Zhang Q, Zhang J. Dou B, et al. Front Pharmacol. 2024 Jun 26;15:1397703. doi: 10.3389/fphar.2024.1397703. eCollection 2024. Front Pharmacol. 2024. PMID: 38989144 Free PMC article.
• A review on the relationship between Arachidonic acid 15-Lipoxygenase (ALOX15) and diabetes mellitus.
  He K, Zhou X, Du H, Zhao J, Deng R, Wang J. He K, et al. PeerJ. 2023 Oct 13;11:e16239. doi: 10.7717/peerj.16239. eCollection 2023. PeerJ. 2023. PMID: 37849828 Free PMC article. Review.
• An overview of pharmacological activities of baicalin and its aglycone baicalein: New insights into molecular mechanisms and signaling pathways.
  Hu Z, Guan Y, Hu W, Xu Z, Ishfaq M. Hu Z, et al. Iran J Basic Med Sci. 2022 Jan;25(1):14-26. doi: 10.22038/IJBMS.2022.60380.13381. Iran J Basic Med Sci. 2022. PMID: 35656442 Free PMC article. Review.
• ML355 Modulates Platelet Activation and Prevents ABT-737 Induced Apoptosis in Platelets.
  Shpakova V, Rukoyatkina N, Al Arawe N, Prilepskaya A, Kharazova A, Sharina I, Gambaryan S, Martin E. Shpakova V, et al. J Pharmacol Exp Ther. 2022 May;381(2):164-175. doi: 10.1124/jpet.121.000973. Epub 2022 Feb 23. J Pharmacol Exp Ther. 2022. PMID: 35197320 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • GlyGen glycoinformatics resource

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal